Record annual revenue of $59.4M was achieved, with positive adjusted EBITDA in all quarters. Investments in radiopharmaceuticals and data platforms drove higher costs, but core research services offset the absence of prior year’s non-recurring revenue. Cash position at year-end was $4.9M.Original d…
Record annual revenue of $59.4M was achieved, with positive adjusted EBITDA in all quarters. Investments in radiopharmaceuticals and data platforms drove higher costs, but core research services offset the absence of prior year’s non-recurring revenue. Cash position at year-end was $4.9M.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
